Company news

ANI Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference

January 27, 2025

ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook

January 12, 2025

ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity

January 1, 2025

ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 29, 2024

ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference

November 25, 2024

ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance

November 7, 2024

ANI Pharmaceuticals to Present at Guggenheim's Inaugural Healthcare Innovation Conference and Jefferies London Healthcare Conference in November

November 3, 2024

ANI Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 8, 2024, at 8: 00 a.m. ET

October 29, 2024

ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.06%

October 24, 2024

ANI Pharmaceuticals to Present New Data Highlighting Membranous Nephropathy Research at American Society of Nephrology Kidney Week 2024

October 23, 2024

ANI Pharmaceuticals Announces the FDA Approval and Launch of Ketoconazole Shampoo, 2%

September 25, 2024

ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences

September 15, 2024

ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences

September 15, 2024

ANI Pharmaceuticals Launches Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution

September 12, 2024

ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger

September 10, 2024

ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences

September 9, 2024

ANI Pharmaceuticals, Inc. Closes $316.25 Million Convertible Senior Notes Offering Including Full Exercise of Initial Purchasers’ Option to Purchase Additional Notes

August 12, 2024

ANI Pharmaceuticals, Inc. Prices Upsized $275.0 Million Convertible Senior Notes Offering

August 6, 2024

ANI Pharmaceuticals, Inc. Announces Proposed Convertible Senior Notes Offering

August 6, 2024

ANI Pharmaceuticals Reports Second Quarter 2024 Financial Results and Raises 2024 Guidance

August 5, 2024

ANI Pharmaceuticals to Discuss Second Quarter 2024 Financial Results on August 6, 2024, at 8: 30 a.m. ET

July 30, 2024

ANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral Powder

July 14, 2024

ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP

July 1, 2024

ANI Pharmaceuticals’ CEO Nikhil Lalwani Named EY Entrepreneur Of The Year® 2024 New Jersey Award Winner

June 24, 2024

ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences

June 23, 2024

ANI Pharmaceuticals to Present at the 2024 Jefferies Global Healthcare Conference

May 28, 2024

ANI Pharmaceuticals Announces the Launch of Kionex® Suspension

May 19, 2024

ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance

May 9, 2024

ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences

April 30, 2024

ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8: 30 a.m. ET

April 17, 2024

ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension

April 8, 2024

ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with Sarcoidosis

April 3, 2024

ANI Pharmaceuticals to Participate at the Piper Sandler Spring Biopharma Symposium

April 2, 2024

ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USP

March 26, 2024

ANI Pharmaceuticals Reports Fourth Quarter and Record Full-Year 2023 Financial Results and Provides 2024 Guidance

February 28, 2024

ANI Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference

February 19, 2024

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024, at 8: 30 a.m. ET

February 6, 2024

ANI Pharmaceuticals to Participate at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

January 28, 2024

ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP

January 22, 2024

ANI Pharmaceuticals Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP

January 15, 2024

ANI Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

November 21, 2023

ANI Pharmaceuticals Reports Record Third Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance

November 7, 2023

ANI Pharmaceuticals to Discuss Third Quarter 2023 Financial Results on November 8, 2023, at 8: 30 a.m. ET

October 24, 2023

ANI Pharmaceuticals Announces FDA Approval and Commercial Availability of New 1-mL Vial Size of Purified Cortrophin® Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares

October 1, 2023

ANI Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023

September 17, 2023

ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Tablets USP

September 11, 2023

ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.1%

August 27, 2023

ANI Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 23, 2023

ANI Pharmaceuticals Appoints Healthcare Executive Matthew J. Leonard to its Board of Directors

August 22, 2023

ANI Pharmaceuticals Reports Record Second Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance

August 8, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 58 decks. Every deck is listed under its year.